Skip to main content

The Design of Covalent-Based Inhibitors

  • 1st Edition, Volume 56 - July 9, 2021
  • Latest edition
  • Editors: Richard A Ward, Neil Grimster
  • Language: English

Annual Report on Medicinal Chemistry series, highlights new advances in the field with this new volume presenting interesting chapters. Each chapter is written by an intern… Read more

Description

Annual Report on Medicinal Chemistry series, highlights new advances in the field with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.

Key features

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in the Annual Report on Medicinal Chemistry series
  • Updated release includes the latest information on The Design of Covalent-Based Inhibitors

Readership

Undergraduates, graduates, academics, and researchers in the field of medicinal chemistry

Table of contents

Preface
Richard Andrew Ward and Neil Grimster

1. The history of covalent inhibitors
Renato A. Bauer

2. Kinetic Mechanisms of Covalent Inhibition
Claire Louise McWhirter

3. Covalent Drugs in Development for Immune-Mediated Diseases
Leonard Sung

4. Chemistry Perspectives of Reversible Covalent Drugs
Jianmin Gao

5. Design of Next-Generation Covalent Inhibitors: Targeting Residues Beyond Cysteine
Lyn Jones

6. Boron and Covalent Inhibition
Andrew Leach

7. Measuring and predicting warhead and residue reactivity
Christopher Rowley

8. Computational Support of Structure-based Targeted Covalent Inhibitor Design
Robert Abel

9. Novel approaches to covalent inhibition
Nir London

10. The future of covalent inhibition
Gyorgy M. Keseru

Product details

  • Edition: 1
  • Latest edition
  • Volume: 56
  • Published: July 9, 2021
  • Language: English

About the editors

RW

Richard A Ward

Richard A. Ward is at AstraZeneca, UK
Affiliations and expertise
AstraZeneca, UK

NG

Neil Grimster

Neil Grimster is at AstraZeneca, USA
Affiliations and expertise
AstraZeneca, USA

View book on ScienceDirect

Read The Design of Covalent-Based Inhibitors on ScienceDirect